421 related articles for article (PubMed ID: 11981011)
1. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome for metastatic papillary renal cell carcinoma patients.
Ronnen EA; Kondagunta GV; Ishill N; Spodek L; Russo P; Reuter V; Bacik J; Motzer RJ
Cancer; 2006 Dec; 107(11):2617-21. PubMed ID: 17083126
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
5. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
6. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients.
Kuthi L; Jenei A; Hajdu A; Németh I; Varga Z; Bajory Z; Pajor L; Iványi B
Pathol Oncol Res; 2017 Jul; 23(3):689-698. PubMed ID: 28032311
[TBL] [Abstract][Full Text] [Related]
8. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
Cheville JC; Lohse CM; Zincke H; Weaver AL; Blute ML
Am J Surg Pathol; 2003 May; 27(5):612-24. PubMed ID: 12717246
[TBL] [Abstract][Full Text] [Related]
10. Localized non-conventional renal cell carcinoma: prediction of clinical outcome according to histology.
Kim SH; Yang HK; Moon KC; Lee ES
Int J Urol; 2014 Apr; 21(4):359-64. PubMed ID: 24224568
[TBL] [Abstract][Full Text] [Related]
11. Neovascularity as a prognostic marker in renal cell carcinoma.
Bauman TM; Huang W; Lee MH; Abel EJ
Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
[TBL] [Abstract][Full Text] [Related]
12. Advanced treatments in non-clear renal cell carcinoma.
Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
[TBL] [Abstract][Full Text] [Related]
13. [Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases].
Nakaigawa N; Yao M; Kondo K; Kishida T; Noguchi K; Kubota Y; Nagashima Y; Kawano N; Inayama Y; Nozawa A
Hinyokika Kiyo; 2006 Jan; 52(1):1-6. PubMed ID: 16479980
[TBL] [Abstract][Full Text] [Related]
14. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
15. The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols.
Daugherty M; Sedaghatpour D; Shapiro O; Vourganti S; Kutikov A; Bratslavsky G
Urol Oncol; 2017 Apr; 35(4):153.e15-153.e20. PubMed ID: 28202224
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
17. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729
[TBL] [Abstract][Full Text] [Related]
18. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urol Oncol; 2011; 29(5):487-91. PubMed ID: 19767221
[TBL] [Abstract][Full Text] [Related]
19. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma.
Zhou H; Zheng S; Truong LD; Ro JY; Ayala AG; Shen SS
Hum Pathol; 2014 Jan; 45(1):59-64. PubMed ID: 24182559
[TBL] [Abstract][Full Text] [Related]
20. Pathobiology and prognosis of chromophobe renal cell carcinoma.
Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
